Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line
- 30 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Human Cell
- Vol. 33 (3), 894-903
- https://doi.org/10.1007/s13577-020-00365-3
Abstract
Dermatofibrosarcoma protuberans (DFSP) is the most common dermal sarcoma; it is characterized by the presence of the COL1A1–PDGFB translocation, which causes the constitutive activation of the platelet-derived growth factor β (PDGFB) signaling pathway. DFSP frequently exhibits local recurrence and is refractory to conventional chemotherapy. Therefore, a novel therapeutic strategy is required for improving the prognosis of DFSP. Although patient-derived cell lines are important tools for pre-clinical studies, currently, only a few such cell lines are available for DFSP in cell banks. Here, we report the establishment of a novel DFSP cell line. Using a surgically resected metastatic tumor tissue from a patient with DFSP, we established a cell line called NCC-DFSP3-C1. The NCC-DFSP3-C1 cells had a COL1A1–PDGFB translocation and retained the same copy number aberrations as the original tumor tissue. NCC-DFSP3-C1 cells exhibited constant growth, spheroid formation, and invasive ability. By screening a drug library, we identified anti-cancer agents with inhibitory effects on the proliferation of NCC-DFSP3-C1 cells; these anti-cancer agents included proteasomal, histone deacetylase, and kinase inhibitors. We concluded that the NCC-DFSP3-C1 cell line may serve as a useful tool for performing basic and pre-clinical studies on DFSP.Keywords
Funding Information
- Fundamental Innovative Oncology Core in the National Cancer Center (29-A-2)
This publication has 37 references indexed in Scilit:
- Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case reportClinical Sarcoma Research, 2013
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaThe Journal of Antibiotics, 2011
- Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic TherapyAnnals of Surgical Oncology, 2010
- Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical TrialsJournal of Clinical Oncology, 2010
- The Impact of Advances in Molecular Genetic Pathology on the Classification, Diagnosis and Treatment of Selected Soft Tissue Tumors of the Head and NeckHead and Neck Pathology, 2010
- Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor Early Growth Response 1 in Synovial SarcomaCancer Research, 2008
- Outcomes of surgery for dermatofibrosarcoma protuberansEuropean Journal of Surgical Oncology, 2004
- Dermatofibrosarcoma protuberansCancer, 2000
- Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberansOncogene, 1998
- Dermatofibrosarcoma protuberansJournal of the American Academy of Dermatology, 1996